Thymosin Alpha-1 — reference
Immune-modulating peptide (Zadaxin), approved in some countries for hepatitis B/C and as an immune adjunct.
Regulatory status
Not FDA-Approved. Not FDA-approved in the United States.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~2 hours. Studied clinically outside the US (e.g. as Zadaxin) with reasonable PK data.
This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Thymosin Alpha-1 FDA-approved?
What is the half-life of Thymosin Alpha-1?
How reliable is that half-life figure?
What cautions are associated with Thymosin Alpha-1?
Does Peptide Plug publish dosing for Thymosin Alpha-1?
Does Peptide Plug sell Thymosin Alpha-1?
Related tools
Free, no account required.
The public research page intentionally does not publish dosing. Pro subscribers can open the separate Protocol Library for structured indication, frequency, duration, notes, and review-first Cycle Builder import when a matching reference is available.
View Protocol Reference